GAD-alum (Diamyd) – a new concept for preservation of residual insulin secretion

Bibliography

• Ludvigsson J, Heding L, Lieden G, Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J (Clin Res Ed) 1983;286:176-8
   PubMed Web of Science ®Google Scholar
• Baekkeskov S, Nielsen JH, Marner B, Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature 1982;10:167-9
   Web of Science ®Google Scholar
• Baekkeskov S, Aanstoot HJ, Christgau S, Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990;347:151-6
   PubMed Web of Science ®Google Scholar
• Christgau S, Schierbeck H, Aanstoot HJ, Pancreatic beta cells express two autoantigenic forms of glutamic acid decarboxylase, a 65-kDa hydrophilic form and a 64-kDa amphiphilic form which can be both membrane-bound and soluble. J Biol Chem 1991;266:21257-64
   PubMed Web of Science ®Google Scholar
• Mehta AK, Ticku MK. An update on GABAA receptors. Brain Res Brain Res Rev 1999;29:196-217
   PubMed Web of Science ®Google Scholar
• Barker JF, Behar T, Li YX, GABA-ergic cells and signals in CNS development. Perspect Dev Neurobiol 1998;5:305-22
   PubMedGoogle Scholar
• Barker JF. GABA as a neurotransmitter and neurogenic signal. Encyclopedia of life sciences. John Wiley & Sons, Chichester, West Sussex; 2004. p. 1-9: published online 03 May 2005, doi: 10.1038/npg.els.0000121
   Google Scholar
• Murinson BB. Stiff-person syndrome. Neurologist 2004;10:131-7
   PubMed Web of Science ®Google Scholar
• Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 1999;131:522-30
   PubMedGoogle Scholar
• Lohmann T, Hawa M, Leslie RD, Immune reactivity to glutamic acid decarboxylase 65 in stiffman syndrome and type 1 diabetes mellitus. Lancet 2000;356:31-5
   PubMed Web of Science ®Google Scholar
• Liu J, Wolfe D, Hao S, Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther 2004;10:57-66
   PubMed Web of Science ®Google Scholar
• Kaplitt MG, Feigin A, Tang C, Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007;369:2097-105
   PubMed Web of Science ®Google Scholar
• Okada Y, Taniguchi H, Schimada C. High concentration of GABA and high glutamate decarboxylase activity in rat pancreatic islets and human insulinoma. Science 1976;194:620-2
   PubMed Web of Science ®Google Scholar
• Bjork E, Kampe O, Andersson A, Karlsson FA. Expression of the 64 kDa/glutamic acid decarboxylase rat islet cell autoantigen is influenced by the rate of insulin secretion. Diabetologia 1992;35:490-3
   PubMed Web of Science ®Google Scholar
• Björk E, Kämpe O, Karlsson FA, Glucose regulation of the autoantigen GAD65 in human pancreatic islets. J Clin Endocrinol Metab 1992;75:1574-6
   PubMedGoogle Scholar
• Kampe O, Andersson A, Bjork E, High-glucose stimulation of 64,000-Mr islet cell autoantigen expression. Diabetes 1989;38:1326-8
   PubMed Web of Science ®Google Scholar
• Rorsman P, Berggren PO, Bokvist K, Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels. Nature 1989;341:233-6
   PubMed Web of Science ®Google Scholar
• Gu XH, Kurose T, Kato S, Suppressive effect of GABA on insulin secretion from the pancreatic beta-cells in the rat. Life Sci 1993;52:687-94
   PubMed Web of Science ®Google Scholar
• Shi Y, Kanaani J, Menard-Rose V, Increased expression of GAD65 and GABA in pancreatic beta-cells impairs first-phase insulin secretion. Am J Physiol Endocrinol Metab 2000;279:E684-694
   Web of Science ®Google Scholar
• Fenalti G, Rowley MJ. GAD65 as a prototypic autoantigen. J Autoimmun 2008;31:228-32
   PubMed Web of Science ®Google Scholar
• Schloot NC, Roep BO, Wegmann DR, T-cell reactivity to GAD65 peptide sequences shared with coxsackie virus protein in recent-onset IDDM, post-onset IDDM patients and control subjects. Diabetologia 1997;40:332-8
   PubMed Web of Science ®Google Scholar
• Karlsson MG, Ludvigsson J. Peptide from glutamic acid decarboxylase similar to coxsackie B virus stimulates IFN-gamma mRNA expression in Th1-like lymphocytes from children with recent-onset insulin-dependent diabetes mellitus. Acta Diabetol 1998;35:137-44
   PubMed Web of Science ®Google Scholar
• Skarsvik S, Puranen J, Honkanen J, Decreased in vitro type 1 immune response against coxsackie virus B4 in children with type 1 diabetes. Diabetes 2006;55:996-1003
   PubMed Web of Science ®Google Scholar
• Kaufman DL, Erlander MG, Clare-Salzler M, Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 1992;89:283-92
   PubMed Web of Science ®Google Scholar
• Atkinson MA, Kaufman DL, Campbell L, Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet 1992;339:458-9
   PubMed Web of Science ®Google Scholar
• Zimmet P. Antibodies to glutamic acid decarboxylase in the prediction of insulin dependency. Diabetes Res Clin Pract 1996;34 (Suppl):S125-131
   PubMed Web of Science ®Google Scholar
• Bingley PJ, Bonifacio E, Williams AJ, Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997;46:1701-10
   PubMed Web of Science ®Google Scholar
• Lernmark A. Controlling the controls: GAD65 autoreactive T cells in type 1 diabetes. J Clin Invest 2002;109:869-70
   PubMed Web of Science ®Google Scholar
• Bach JF. Autoimmunity and type I diabetes. Trends Endocrinol Metab 1997;8:71-4
   PubMed Web of Science ®Google Scholar
• Bach JF. New concepts of the etiopathogenesis and treatment of insulin-dependent diabetes mellitus. Clin Rev Allergy Immunol 2000;19:217-25
   PubMed Web of Science ®Google Scholar
• Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-9
   PubMed Web of Science ®Google Scholar
• Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia 2003;46:305-21
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Bojestig M, Arnqvist HJ, Hermansson G, Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994;330:15-8
   PubMed Web of Science ®Google Scholar
• Nordfeldt S, Ludvigsson J. Severe hypoglycemia in children with IDDM. A prospective population study, 1992-1994. Diabetes Care 1997;20:497-503
   PubMed Web of Science ®Google Scholar
• Steffes MW, Sibley S, Jackson M, Thomas W. beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-6
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Samuelsson U, Ernerudh J, Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. Arch Dis Child 2001;85:149-54
   PubMed Web of Science ®Google Scholar
• Heinze E. Immunoglobulins in children with autoimmune diabetes mellitus. Clin Exp Rheumatol 1996;14 (Suppl 15):S99-102
   PubMed Web of Science ®Google Scholar
• Dupré J, Stiller CR, Gent M, Clinical trials of cyclosporin in IDDM. Diabetes Care 1988;11 (Suppl 1):37-44
   PubMed Web of Science ®Google Scholar
• Silverstein J, Maclaren N, Riley W, Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988;319:599-604
   PubMed Web of Science ®Google Scholar
• Coutant R, Landais P, Rosilio M, Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia 1998;41:1040-6
   PubMed Web of Science ®Google Scholar
• Rother KI, Brown RJ, Morales MM, Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes. Diabetes Care 2009;32(7):1250-5
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361(22):2143-52
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman SE, Masharani U, A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-9
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Vandemeulebroucke E, Ziegler AG, Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-608
   PubMed Web of Science ®Google Scholar
• Skyler JS, Krischer JP, Wolfsdorf J, Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial–Type 1. Diabetes Care 2005;28:1068-76
   PubMed Web of Science ®Google Scholar
• Näntö-Salonen K, Kupila A, Simell S, Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008;372(9651):1746-55
   PubMed Web of Science ®Google Scholar
• Raz I, Elias D, Avron A, beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001;358:1749-53
   PubMed Web of Science ®Google Scholar
• Schloot NC, Meierhoff G, Lengyel C, Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 2007;23:276-85
   PubMed Web of Science ®Google Scholar
• Ludvigsson J. Adequate doses of autoantigen administered using the appropriate route may create tolerance and stop autoimmunity. Diabetologia 2009;52(1):175-6
   PubMed Web of Science ®Google Scholar
• Kaufman DL, Clare-Salzler M, Tian J, Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993;366:69-72
   PubMed Web of Science ®Google Scholar
• Tisch R, Yang XD, Singer SM, Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993;366:72-5
   PubMed Web of Science ®Google Scholar
• Petersen JS, Karlsen AE, Markholst H, Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in NOD mice. Diabetes 1994;43:1478-84
   PubMedGoogle Scholar
• Pleau JM, Fernandez-Saravia F, Esling A, Prevention of autoimmune diabetes in nonobese diabetic female mice by treatment with recombinant glutamic acid decarboxylase (GAD 65). Clin Immunol Immunopathol 1995;76:90-5
   PubMedGoogle Scholar
• Tian J, Atkinson MA, Clare-Salzler M, Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996;183:1561-7
   PubMed Web of Science ®Google Scholar
• Tian J, Clare-Salzler M, Herschenfeld A, Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 1996;2:1348-53
   PubMed Web of Science ®Google Scholar
• Tisch R, Liblau RS, Yang XD, Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998;47:894-9
   PubMed Web of Science ®Google Scholar
• Plesner A, Worsaae A, Dyrberg T, Immunization of diabetes-prone or non-diabetes-prone mice with GAD65 does not induce diabetes or islet cell pathology. J Autoimmun 1998;11:335-41
   PubMed Web of Science ®Google Scholar
• Yoon JW, Yoon CS, Lim HW, Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science 1999;284:1183-7
   PubMed Web of Science ®Google Scholar
• Tisch R, Wang B, Weaver DJ, Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J Immunol 2001;166:2122-32
   PubMed Web of Science ®Google Scholar
• Jun HS, Chung YH, Han J, Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase. Diabetologia 2002;45:668-76
   PubMed Web of Science ®Google Scholar
• Agardh CD, Cilio CM, Lethagen A, Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005;19:238-46
   PubMed Web of Science ®Google Scholar
• Agardh C-D, Lynch K, Palmér M, GAD65 vaccination significantly reduces insulin dependence at five years follow-up in a dose escalating study in adult-onset autoimmune diabetes patients. Diabetologia 2008;51 (Suppl 1):S230
   Google Scholar
• Ludvigsson J, Faresjö M, Hedman M, GAD65 treatment and residual insulin secretion in recent onset type 1 diabetes. N Engl J Med 2008;30:1909-20
   Web of Science ®Google Scholar
• Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Mixed meal tolerance test versus the glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-71
   PubMed Web of Science ®Google Scholar
• Madsbad S, Alberti KG, Binder C, Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J 1979;2:1257-9
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998;128:517-23
   PubMed Web of Science ®Google Scholar
• Wahren J, Ekberg K, Jornvall H. C-peptide is a bioactive peptide. Diabetologia 2007;50:503-9
   PubMed Web of Science ®Google Scholar